Intellia Thera CS (NTLA)

$22.15 0.32 (1.42%)

16:00 EDT NTLA Stock Quote Delayed 30 Minutes

Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet

By Joey Frenette, InvestorPlace Contributor Jun 28, 2024

Undiscovered biotech stocks can be risky but rewarding, especially when it involves mid-cap stocks with promise and no profit.

You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.

Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich

3 Gene Editing Stocks That Could Make Your Grandchildren Rich

Volume:

Previous Close -

Market Cap 1.95B

PE Ratio -18.93

EPS -1.17

Volume (Avg. Vol.) 1.43M

Day's Range $21.60 - $22.46

52-Week Range $19.37 - $46.50

Dividend & Yield N/A (N/A)

NTLA Stock Predictions, Articles, and Intellia Thera CS News

Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024

By Divya Premkumar, InvestorPlace Contributor Jun 21, 2024

Investors looking for companies with high growth potential should consider investing in these three strong buy Cathie Wood stocks.

The 3 Best Biotech Stocks to Buy in June 2024

By Shane Neagle, InvestorPlace Contributor Jun 5, 2024

Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia.

NTLA Stock Earnings: Intellia Therapeutics Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings May 9, 2024

NTLA stock results show that Intellia Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Just Say No to Drugs: 3 Pharma Stocks to Avoid

By Shane Neagle, InvestorPlace Contributor May 8, 2024

Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios.

Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street’s Radar

By Joey Frenette, InvestorPlace Contributor May 3, 2024

The gene editing stocks are worth tuning into as some investors out there discount their innovative, albeit early-stage pipelines.

3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

By Ian Cooper, InvestorPlace Contributor May 2, 2024

Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion.

Hot Stocks: The 3 Best Opportunities for Investing in Biotech

By Chandler Capital, InvestorPlace Contributor Mar 21, 2024

Biotech stocks can offer some of the best risk vs. reward payoff in the stock market. These three are ones to buy now.

3 Stocks That Could Be the Next Big Thing in Gene Editing

By Ian Cooper, InvestorPlace Contributor Mar 21, 2024

Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks.

3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential

By Ian Cooper, InvestorPlace Contributor Feb 19, 2024

Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts.

3 Gene Editing Stocks With Unprecedented Surge Potential

By Ian Cooper, InvestorPlace Contributor Feb 13, 2024

While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.

The 3 Most Undervalued Biotech Stocks to Buy in February 2024

By Ian Cooper, InvestorPlace Contributor Feb 8, 2024

With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

By Ian Cooper, InvestorPlace Contributor Jan 31, 2024

Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics, for example.

3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024

By Ian Cooper, InvestorPlace Contributor Jan 22, 2024

Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune.

Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job Cuts

By William White, InvestorPlace Writer Jan 5, 2024

Intellia Therapeutics layoffs are in the news on Friday as the biotech company prepares to cut its total workforce by 15% to reduce costs.

3 Gene-Editing Stocks With the Potential to Mint Millionaires

By Alex Sirois, InvestorPlace Contributor Dec 13, 2023

Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.

3 Biotech Stocks That Are Betting on the Future of Gene Editing

By Chris Markoch, InvestorPlace Contributor Nov 9, 2023

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

The 3 Most Promising Biotech Stocks to Own Now

By Michael Que, InvestorPlace Contributor Aug 31, 2023

These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential.

The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023

By Marie Brodbeck, InvestorPlace Contributor Jul 24, 2023

These three undervalued biotech stocks could have plenty of room to run if their efforts to push out promising pipeline drugs are successful.

The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023

By Gabriel Osorio-Mazzilli, InvestorPlace Contributor Jul 20, 2023

These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector.

Why Is Intellia (NTLA) Stock Up 5% Today?

By Larry Ramer, InvestorPlace Contributor Jun 12, 2023

NTLA stock is trending on social media and is up over 5%. The drugmaker reported new, positive results from its gene-edited treatment.

Intellia Thera CS (NTLA)

Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet

You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.

Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich

3 Gene Editing Stocks That Could Make Your Grandchildren Rich

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Intellia Thera CS (NTLA)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

NTLA Stock Predictions, Articles, and Intellia Thera CS News

Subscriber Sign in